logo
Menu

This search function provides links to outputs produced by NIHR Innovation Observatory. These are briefing notes or reports on new or repurposed technologies. This search will not return all technologies currently in development as these outputs are produced as required for our stakeholders.

Innovation Observatory > Reports > Drugs > Atezolizumab in combination with chemotherapy for non-small-cell lung cancer- neoadjuvant and adjuvant

< Back

Atezolizumab in combination with chemotherapy for non-small-cell lung cancer- neoadjuvant and adjuvant

Drugs

Cancer and Palliative Care

October 2020


Atezolizumab in combination with chemotherapy is in clinical development as a neoadjuvant and adjuvant treatment for stage II, IIIA, or select IIIB non-small-cell lung cancer (NSCLC). NSCLC is the most common type of lung cancer. Early-stage lung cancer is typically treated with surgery consisting of removing either part of or the whole of the lung, followed by chemotherapy and/or radiotherapy (adjuvant). However, the long-term outlook for patients undergoing this treatment pathway is still poor. Treatment with medicines prior to surgery (neoadjuvant) and adjuvant (treatment after primary treatment) may provide better long-term survival prospects and reduce the risk of disease recurrence for patients with resectable NSCLC.
Atezolizumab is a type of protein called an antibody, which can bind to a protein called programmed death-ligand 1 (PD-L1) to prevent it from interacting with its target (PD-1). Thus, helping immune cells kill cancer cells and is used to treat many different types of cancer that express PD-L1. If licensed, atezolizumab would offer a neoadjuvant and adjuvant treatment option for patients with stage II, IIIA, or select IIIB NSCLC.

Innovation Observatory Voice 0

Leave a Reply

Your email address will not be published. Required fields are marked *

Post Comment

Download Full Article



 

Connect to the Innovation Observatory

Twitter

Load More Related Posts

Get Alerts